Chelsea Therapeutics (Nasdaq: CHTP) was nearly an instant double as shares closed up 92% today after receiving a positive advisory committee vote for its NOH drug Northera.
 
The trading action would lead investors to conclude it was a blowout, and in FDA advisory committee terms it was, a 16-1 decision recommending the agency approve the drug.
 
Before investors get too excited, remember Chelsea has been here before. This is not Northera's first trip in front of the FDA. Its not even Northera's first trip with a positive advisory committee vote in hand. That didn't stop it from its most recent rejection. And the FDA seemingly has not warmed up to the drug; a large part of today's gain was just making up for the 29% plunge that happened when the FDA's briefing documents came out ahead of the advisory panel.
 
In this video, Motley Fool health care analyst David Williamson discusses the FDA biggest concern about Northera, why Chelsea's balance sheet is a big problem, and whether he thinks the drug will be approved on, yes, Valentine's day.
 
 

The best way to play the biotech space is to find companies that shun the status quo and instead discover revolutionary, groundbreaking technologies. In the Motley Fool's brand-new FREE report "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that big pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.

 

David Williamson has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.